Description: Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products in the People's Republic of China. The company provides products for therapeutic areas, including anti-tumor, anti-infection, central nervous system diseases, oncology, metabolic and autoimmune diseases, etc. Its principal products include Ameile, Hansoh Xinfu, Pulaile, Zefei, Xintai, Xinmei, Gainuo, Hengmu, Mailingda, Hengsen, XINYUE, Saint Luolai, Fulaimei, Pulaitan, Tanneng, Ameining, Oulanning, Ruibote, Fulaidi, Fulairui, and Puruian tablets. The company serves pharmaceutical product distributors. It has licence agreements with GSK plc to develop, manufacture, and commercialise HS20089 and HS-20093; GlaxoSmithKline Intellectual Property (No.4) Limited to develop, manufacture, and commercialize HS-20089; and Biotheus Inc. to develop, produce, and commercialize bispecific antibody-drug conjugate product, as well as collaboration agreement with Antengene Corporation Limited to commercialize selinexor and any product containing or comprising Selinexor. In addition, it engages in trading business. The company was founded in 1995 and is headquartered in Shanghai, the People's Republic of China. Hansoh Pharmaceutical Group Company Limited is a subsidiary of Stellar Infinity Company Ltd.
Home Page: www.hspharm.com
287 Xiangke Road
Shanghai,
201210
China
Phone:
86 40 0828 5227
Officers
| Name | Title |
|---|---|
| Ms. Huijuan Zhong | Chairlady, CEO & President |
| Dr. Aifeng Lyu | Executive Director |
| Ms. Yuan Sun | Executive Director |
| Mr. Min Hu | VP & CFO |
| Dr. Chih-Hung Lee | Chief of Science Officer |
| Mr. Chuanhe Xu | Senior Vice President |
| Mr. Weiyong Sun | Chief Commercial Officer |
| Ms. Shengli Zhong | Joint Company Secretary & Senior VP |
| Ms. Sze Wai Tam | Joint Company Secretary |
Exchange: PINK
Country: US : United States of America
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 26.8571 |
| Price-to-Book MRQ: | 3.0718 |
| Price-to-Sales TTM: | 1.0959 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 9099 |